Display options
Cite
Le Noci V, Sommariva M, Tortoreto M, et al. Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology. 2016;5(11):e1234571doi: 10.1080/2162402X.2016.1234571.
Le Noci, V., Sommariva, M., Tortoreto, M., Zaffaroni, N., Campiglio, M., Tagliabue, E., Balsari, A., & Sfondrini, L. (2016). Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology, 5(11), e1234571. https://doi.org/10.1080/2162402X.2016.1234571
Le Noci, Valentino, et al. "Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor." Oncoimmunology vol. 5,11 (2016): e1234571. doi: https://doi.org/10.1080/2162402X.2016.1234571
Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L. Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016. PMID: 27999750; PMCID: PMC5139640.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016.

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Oncoimmunology

Valentino Le Noci, Michele Sommariva, Monica Tortoreto, Nadia Zaffaroni, Manuela Campiglio, Elda Tagliabue, Andrea Balsari, Lucia Sfondrini

Affiliations

  1. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy; Molecular Targeting Unit, Milan, Italy.
  2. Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, Italy.
  3. Molecular Targeting Unit , Milan, Italy.
  4. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano , Milan, Italy.

PMID: 27999750 PMCID: PMC5139640 DOI: 10.1080/2162402X.2016.1234571

Abstract

Due to their constant exposure to inhaled antigens, lungs represent a particularly immunosuppressive environment that limits excessive immune responses; however, cancer cells can exploit this unique environment for their growth. We previously described the ability of aerosolized CpG-ODN combined with Poly(I:C) (TLR9 and TLR3 agonists, respectively) to promote antitumor immunity in a B16 melanoma lung metastasis model. Here, we explored the possibility of improving the therapeutic efficacy of TLR9/TLR3 agonist combinations by including in the inhalant either an antibody directed to both Ly6G and Ly6C markers to locally deplete myeloid-derived suppressive cells (MDSCs) or IFNα to directly activate the natural killer (NK) and macrophage innate immune cells in the lung. Addition of nebulized anti-MDSC antibody RB6-8C5 to aerosolized CpG-ODN/Poly(I:C) resulted in reduced mRNA levels of immunsuppressive molecules (IL10, Arg-1, and Nos2), increased activation of resident NK cells and improved treatment outcome, with a significant reduction in established B16 melanoma lung metastases compared to treatment with CpG-ODN/Poly(I:C) alone. Likewise, addition of aerosolized IFNα led to increased mRNA levels of proinflammatory cytokines (IL15 and IFNγ) in the lung and recruitment of highly activated NK cells, with no evident signs of toxicity and with a significantly improved antitumor effect as compared with aerosolized CpG-ODN/Poly(I:C). Combining both IFNα and RB6-8C5 with CpG-ODN/Poly(I:C) did not produce an additive effect compared to IFNα + CpG-ODN/Poly(I:C) or RB6-8C5 + CpG-ODN/Poly(I:C). Our results indicate that the inhalation therapy is a feasible and non-invasive strategy to deliver immunodulatory molecules, including antibodies and cytokines that reprogram the lung tumor microenvironment to foster immune destruction of tumors.

Keywords: IFNα; inhalation therapy; TLR agonists; lung microenvironment; tumor

References

  1. Eur J Immunol. 2010 Dec;40(12):3347-57 - PubMed
  2. Eur J Cancer. 1990;26(6):738-40 - PubMed
  3. J Immunol. 2009 Jan 1;182(1):240-9 - PubMed
  4. J Neurochem. 2013 Apr;125(1):74-88 - PubMed
  5. J Exp Med. 1978 May 1;147(5):1314-33 - PubMed
  6. Curr Cancer Drug Targets. 2015;15(7):604-12 - PubMed
  7. Oncoimmunology. 2015 May 27;4(10):e1040214 - PubMed
  8. J Leukoc Biol. 2016 Jun;99(6):794 - PubMed
  9. PLoS One. 2013;8(3):e58913 - PubMed
  10. Cancer Sci. 2008 Aug;99(8):1663-9 - PubMed
  11. J Immunol. 2012 Dec 15;189(12):5602-11 - PubMed
  12. Blood. 2007 May 15;109(10):4336-42 - PubMed
  13. Hepatology. 2009 Sep;50(3):799-807 - PubMed
  14. Eur Cytokine Netw. 2000 Mar;11(1):99-104 - PubMed
  15. Int J Cancer. 2013 Jul 15;133(2):383-93 - PubMed
  16. PLoS One. 2012;7(7):e40677 - PubMed
  17. Eur J Pharm Biopharm. 2005 Oct;61(3):214-8 - PubMed
  18. J Immunol. 2008 Oct 15;181(8):5791-802 - PubMed
  19. J Control Release. 2014 Dec 28;196:344-54 - PubMed
  20. MAbs. 2014;6(6):1638-48 - PubMed
  21. Semin Cancer Biol. 2012 Aug;22(4):275-81 - PubMed
  22. Eur J Cancer. 1990;26(6):740-1 - PubMed
  23. Biochim Biophys Acta. 2002 Feb 13;1589(1):1-13 - PubMed
  24. Surgery. 2006 Aug;140(2):297-306 - PubMed
  25. Antimicrob Agents Chemother. 2015 Jul;59(7):4162-72 - PubMed
  26. Clin Cancer Res. 2011 May 1;17(9):2619-27 - PubMed
  27. Cancer Res. 2012 Aug 15;72(16):3906-11 - PubMed
  28. Eur J Immunol. 2009 Dec;39(12):3538-51 - PubMed
  29. J Immunol. 2015 Sep 15;195(6):2818-28 - PubMed
  30. Immunobiology. 2015 Feb;220(2):236-42 - PubMed
  31. Innate Immun. 2015 Aug;21(6):626-34 - PubMed
  32. J Exp Med. 2010 Sep 27;207(10):2053-63 - PubMed
  33. Oncologist. 2001;6(1):34-55 - PubMed

Publication Types